1) 盛田順子，肥塚直美. GH/IGF-Ⅰ作用とその差異. ホルモンと臨床 2005; 53(8): 763-768.
2) Root AW, Diamond FB Jr. Regulation and clinical assessment of growth hormone secretion. Endocrine 2000; 12(2): 137-145.
3) 羽二生邦彦. ヒト成長ホルモンの分泌調節機構と各種疾患におけるGH血中濃度. 内分泌・
糖尿病科 2002; 15(suppl.1): 209-222.
4) 加治秀介，千原和夫. GH分泌調節機構. 岡田義昭 監修. ヒト成長ホルモン．第1版.：メ ディカルレビュー社；1994; 174-194.
5) Cuttler L. The regulation of growth hormone secretion. Endocrinol Metab Clin North Am.1996; 25(3):
541-571.
6) 高野順子，高野幸路. GH分泌の経年的変化. ホルモンと臨床 2005; 53(8): 753-762.
7) Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998; 19(6): 717-797.
8) 對馬敏夫. GHの代謝作用. 岡田義昭 監修. ヒト成長ホルモン．第1版.：メディカルレビ ュー社；1994; 74-97.
9) 島津章. 成長ホルモンの代謝作用（糖、脂質、蛋白、電解質）. 内分泌・糖尿病科 2002;
15(suppl.1): 129-137.
10) De Boer H, Blok GJ, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults.
Endocr Rev 1995; 16(1): 63-86.
11) Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A Review. J Clin Endocrinol Metab 1998; 83(2): 382-395.
12) Conceicao FL, Bojensen A, Jorgensen JOL, Christiansen JS. Growth hormone therapy in adults. Front Neuroendocrinol 2001; 22: 213-246.
13) 島津章，千原和夫，横越浩，富永篤，宗宮基，大山知代，他. 成人ソマトロピン（GH）欠損 症の病態と諸問題. ホルモンと臨床1997; 45(増刊号): 120-128.
14) Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson BA. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinologica 1993; 129: 195-200.
15) 山路徹. 下垂体機能低下症の長期予後. ホルモンと臨床1998; 46(8): 677-682.
16) Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency:
Summary statement of the Growth Hormone Research society workshop on adult growth hormone deficiency. J Clin Endocrinol Metab 1998; 83(2): 379-381.
17) 入江實，伊藤嘉晃，宮下洋，白井厚治. 本邦における成人GH欠損症例の合併症に関する検 討（厚生省間脳下垂体機能障害調査研究班アンケートから）厚生省特定疾患間脳下垂体機能 障害調査研究班 平成6年度総括研究事業報告書.；1995．p. 37-40.
18) Markussis V, Beshyah SA, Fisher C, Sharp P, Nicolaides AN, Johnston DG. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 1992;
グロウジェクト 2.5 臨床に関する概括評価
340: 1188-1192.
19) Elhadd TA, Abdu TA, Oxtoby J, Kennedy G, McLaren M, Neary R, et al. Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency. J Clin Endocrinol Metab 2001; 86(9): 4223-4232.
20) Hopkins KD, Lehmann ED, Gosling RG, Parker JR, Sönksen PH. Biochemical correlates of aortic distensibility in vivo in normal subjects. Clin Sci(Lond) 1993; 84: 593-597.
21) Johansson JO, Landin K, Tengborn L, Rosen T, Bengtsson BA. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arteriosclerosis and Thrombosis 1994;
14(3): 434-437.
22) Capaldo B, Patti L, Oliviero U, Longobardi S, Pardo F, Vitale F, et al. Increased arterial intima-media thickness in childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 1997; 82(5):
1378-1381.
23) Murata M, Kaji H, Mizuno I, Sakurai T, Iida K, Okimura Y, et al. A study of carotid intima-media thickness in GH-deficient Japanese adults during onset among adults and children. Eur J Endocrinol 2003; 148: 333-338.
24) Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285-288.
25) Bülow B, Hagmar L, Mikoczy Z, Nordström CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol(Oxf) 1997; 46: 75-81.
26) 加藤讓. 間脳下垂体疾患の診療の進歩と課題. 日本内分泌学会雑誌 2003; 79(Suppl): 5-8.
27) 有田和徳，平野宏文，栗栖薫，富永篤. 間脳下垂体腫瘍における成長ホルモン分泌能 厚生 労働科学研究費補助金難治性疾患克服研究事業 間脳下垂体機能障害に関する調査研究；
平成17年度 総括・分担研究報告書.；2006．p. 75-79.
28) Hartman ML, Crowe BJ, Biller BMK, Ho KKY, Clemmons DR, Chipman JJ. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 2002;
87(2): 477-485.
29) 千原和夫（主任研究者）. 成人成長ホルモン分泌不全症の診断と治療の手引き（平成17年度 改訂）．厚生労働科学研究費補助金難治性疾患克服研究事業 間脳下垂体機能障害に関する調 査研究； 平成17年度 総括・分担研究報告書.；2006．p. 121-124.
30) Monson JP. Long-term experience with GH replacement therapy: efficacy and safety. Eur J Endocrinol 2003; 148: S9-S14.
31) Attanasio AF, Bates PC, Ho KKY, Webb SM, Ross RJ, Strasburger CJ, et al. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status－
3-year results from the HypoCCS Database. J Clin Endocrinol Metab 2002; 87(4): 1600-1606.
32) Salomon F, Cuneo RC, Hesp R, Sönksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321; 1797-1803.
グロウジェクト 2.5 臨床に関する概括評価
33) Bengtsson BA, Eden S, Lönn L, Kvist H, Stokland A, Lindstedt G, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993; 76(2):
309-317.
34) Ahmad AM, Hopkins MT, Thomas J, Ibrahim H, Fraser WD, Vora JP. Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement. Clin Endocrinol (Oxf) 2001; 54: 709-717.
35) 入江實，鎮目和夫，加藤讓，高野加寿恵，宮地幸隆，千原和夫，他. 遺伝子組換えヒト成長 ホルモンの成人成長ホルモン欠損症に対するプラセボ対照二重盲検比較試験. 薬理と治療 1997; 25(2): 199-211.
36) 入江實，加藤讓，高野加寿恵，宮地幸隆，千原和夫，田中敏章，他. 遺伝子組換えヒト成長 ホルモンの成人成長ホルモン欠損症に対する長期試験. 薬理と治療1997; 25(2): 213-221.
37) 入江實，加藤讓，高野加寿恵，宮地幸隆，千原和夫，田中敏章，他. 遺伝子組換えヒト成長 ホルモンの成人成長ホルモン欠損症に対する第Ⅲ相臨床試験. 薬理と治療 1997; 25(2):
223-235.
38) Ter Maaten JC, De Boer H, Kamp O, Stuurman L, Van der Veen EA. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. J Clin Endocrinol Metab 1999; 84(7): 2373-2380.
39) Hernberg-Stahl E, Luger A, Abs R, Bengtsson BA, Feldt-Rasmussen U, Wilton P, et al. Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. J Clin Endocrinol Metab 2001; 86(11): 5277-5281.
40) Burman P, Broman JE, Hetta J, Wiklund I, Erfurth EM, Hagg E, et al. Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab 1995; 80(12): 3585-3590.
41) McGauley GA. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatrica Scandinavica. Supplement 1989; 356: 70-72.
42) 河野斉. 成人の成長ホルモン欠損症－成長ホルモン生涯補充治療の必要性－. 小児内科 1999; 31(9): 1203-1208.
43) Chihara K, Koledova E, Shimatsu A, Kato Y, Kohno H, Tanaka T, et al. Adult GH deficiency in Japanese patients: effects of GH treatment in a randomised, placebo-controlled trial. Eur J Endocrinol 2004; 151: 343-350.
44) Chihara K, Koledova E, Shimatsu A, Kato Y, Kohno H, Tanaka T, et al. An individualized GH dose regimen for long-term GH treatment in Japanese patients with adult GH deficiency. Eur J Endocrinol 2005; 153: 57-65.
45) Chihara K, Kato Y, Kohno H, Takano K, Tanaka T, Teramoto A, et al. Efficacy and safety of growth hormone (GH) in the treatment of adult Japanese patients with GH deficiency: A randomised, placebo-controlled study. Growth Horm IGF Res 2006; 16: 132-142.
46) Chihara K, Kato Y, Takano K, Shimatsu A, Kohno H, Tanaka T, et al. Effect of growth hormone
グロウジェクト 2.5 臨床に関する概括評価
treatment on trunk fat accumulation in adult GH-deficient Japanese patients: a randomised, placebo-controlled trial. Curr Med Res Opin 2006; 22(10): 1973-1979.
47) Chihara K, Shimatsu A, Kato Y, Kohno H, Tanaka T, Takano K, et al. Growth hormone (GH) effects on central fat accumulation in adult Japanese GH deficient patients: 6-month fixed-dose effects persist during second 6-month individualized-dose phase. Endocrine Journal 2006; 53(6): 853-858.
48) Nakamura T, Tokunaga K, Shimomura I, Nishida M, Yoshida S, Kotani K, et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men.
Atherosclerosis 1994; 107(2): 239-246.
49) Ito H, Nakasuga K, Ohshima A, Maruyama T, Kaji Y, Harada M, et al. Detection of cardiovascular risk factors by indices of obesity obtained from anthropometry and dual-energy X-ray absorptiometry in Japanese individuals. Int J Obes(Lond) 2003; 27: 232-237.
50) American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children-2003 update. Endocr Pract 2003; 9(1): 64-76.
51) Simpson H, Savine R, Sönksen P, Bengtsson BA, Carlsson L, Christiansen JS, et al. Growth hormone replacement therapy for adults: Into the new millennium. Growth Horm IGF Res 2002; 12: 1-33.
52) 島津章，藤枝憲二，羽二生邦彦，田中敏章，横谷進，宮地幸隆，他. IRMA キットを用いた
IGF-Ⅰ，IGF-Ⅱ，IGFBP-3 測定の臨床的検討 第1報 成人期における検討. ホルモンと臨
床 1996; 44(10): 1129-1138.
53) 加治秀介，櫻井達也，千原和夫. 成人 GH欠損症の実態調査の概要 成長科学協会 研究年報 2000; 24-34.
54) Abdu TAM, Neary R, Elhadd TA, Akber M, Clayton RN. Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities. Clin Endocrinol(Oxf) 2001; 55: 209-216.
55) Erfurth EMT, Bülow B, Hagmar LE. Is vascular mortality increased in hypopituitarism? Pituitary 2000; 3: 77-81.
56) Sowers JR. Obesity as a cardiovascular risk factor. Am J Med 2003; 115 Suppl 8A: 37S-41S.
57) Van Gaal LF, Mertens IL, Abrams PJ. Health risks of lipodystrophy and abdominal fat accumulation:
therapeutic possibilities with leptin and human growth hormone. Growth Horm IGF Res 2003; 13 Suppl 1: S4-S9.
58) Johansson JO, Landin K, Tengborn L, Rosen T, Bengtsson BA. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arteriosclerosis and Thrombosis 1994;
14(3): 434-437.
59) Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: A metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 2004; 89(5): 2192-2199.
60) Elam MB, Wilcox HG, Solomon SS, Heimberg M. In vivo growth hormone treatment stimulates secretion of very low density lipoprotein by the isolated perfused rat liver. Endocrinology 1992;
グロウジェクト 2.5 臨床に関する概括評価
131(6): 2717-2722.
61) Sjöberg A, Oscarsson J, Eden S, Olofsson SO. Continuous but not intermittent administration of growth hormone to hypophysectomized rats increases apolipoprotein-E secretion from cultured hepatocytes. Endocrinology 1994; 134(2): 790-798.
62) Christ ER, Cummings MH, Albany E, Umpleby AM, Lumb PJ, Wierzbicki AS, et al. Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency: A stable isotope study. J Clin Endocrinol Metab 1999; 84(1):
307-316.
63) Christ ER, Cummings MH, Jackson N, Stolinski M, Lumb PJ, Wierzbicki AS, et al. Effects of growth hormone (GH) replacement therapy on low-density lipoprotein apolipoprotein B100 kinetics in adult patients with GH deficiency: A stable isotope study. J Clin Endocrinol Metab 2004; 89(4): 1801-1807.
64) Gibney J, Wallace JD, Spinks T, Schnorr L, Ranicar A, Cuneo RC, et al.: The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 1999; 84(8): 2596–2602.
65) Rosen T, Wiren L, Wilhelmsen L, Wiklund I, Bengtsson BA. Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol(Oxf) 1994; 40: 111-116.
66) Wiren L, Whalley D, McKenna S, Wilhelmsen L. Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: validation of the measure by rasch analysis. Clin Endocrinol(Oxf) 2000; 52: 143-152.
67) Mercola KE, Cline MJ, Golde DW. Growth hormone stimulation of normal and leukemic human T-lymphocyte proliferation in vitro. Blood 1981; 58(2): 337-340.
68) Moshang T, Rundle AC, Graves DA, Nickas J, Johanson A, Meadows A. Brain tumor recurrence in children treated with growth hormone: The National Cooperative Growth Study experience. J Pediatr 1996; 128(5 pt 2): S4-S7.
69) Takano A, Haruta T, Iwata M, Usui I, Uno T, Kawahara J, et al. Growth hormone induces cellular insulin resistance by uncoupling phosphatidylinositol 3-kinase and its downstream signals in 3T3-L1 adipocytes. Diabetes 2001; 50: 1891-1900.
70) Hwu CM, Kwok CF, Lai TY, Shih KC, Lee TS, Hsiao LC, et al. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J Clin Endocrinol Metab 1997; 82(10): 3285-3292.
71) Ho KY, Weissberger AJ. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the Renin-Angiotensin system. Metabolism 1990; 39(2): 133-137.
72) Porretti S, Giavoli C, Ronchi C, Lombardi G, Zaccaria M, Valle D, et al. Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T4 therapy become mandatory? J Clin Endocrinol Metab 2002; 87(5): 2042-2045.
73) Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the